In this observational study, the researchers found all regimens of anticoagulants were far superior to no anticoagulants in COVID-19 patients. More specifically, patients on both a “therapeutic” or full dose, and those on a “prophylactic” or lower dose, showed about a 50 percent higher chance of survival, and roughly a 30 percent lower chance of intubation, than those not on anticoagulants. The researchers looked at six different anticoagulant regimens, including both oral and intravenous dosing, within both therapeutic and prophylactic groups. They observed that therapeutic and prophylactic subcutaneous low-molecular-weight heparin, and therapeutic oral apixaban, may lead to better results.
Referring a patient is easy. Just click the “Refer a Patient Online” button.
